Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prevagen

This article was originally published in The Tan Sheet

Executive Summary

A dietary supplement consisting of jellyfish protein aequorin and claiming "anti-aging activity" in University of Wisconsin-Milwaukee lab studies should be in stores by Sept. 1, 2007, Prevagen developer Quincy Bioscience announced at the Expo West tradeshow in Anaheim, Calif. March 23. The product acts as a calcium-binding protein, replacing those that are depleted "in several areas of the body as part of the aging process," according to the Madison, Wis.-based firm. Prevagen can be "be marketed as a dietary supplement and in the future go through clinical trials with the goal of getting FDA approval towards neurodegenerative disease," the company notes...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS099268

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel